Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Enalapril Inhibits Growth and Proliferation of Various Tissues in Rat Normotensive Four–Sixths Kidney Ablation Nephropathy

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most experimental studies on kidney proliferation and its attenuation by angiotensin–converting enzyme inhibitors were performed in the rat hypertensive remnant–kidney model with a five–sixths kidney ablation. The developing hypertension rose the objections on the hypertension and its treatment in control rats. A normotensive four–sixths remnant–kidney model (Nx) was elaborated, compared with sham–operated (S) animals, and a subantihypertensive dosage of enalapril (E) was administered for 4 weeks of intensive kidney tissue proliferation (NxE). The pair–fed groups increased their body weight and blood pressure comparably. Moderately increased plasma creatinine and urea concentrations were found in the Nx group; markedly increased levels in the NxE group. Nx increased proteinuria, and E attenuated its increase. The remnant–kidney weight (Nx 912±31 vs. S 1,111±36 mg, p<0.001) was still lower, but collagen (Col; Nx 164±2 vs. S 148±5 mg/100 g, p<0.05) and tubular protein/DNA ratio (Nx 26.2±10.8 vs. S 9.8±1.0, p<0.05) increased markedly in the Nx group; E attenuated the kidney growth (NxE 719±31 vs. Nx 912±31 mg, p<0.01) and decreased the tubular protein/DNA ratio remarkably (NxE 15.3±10.5 vs. Nx 26.2 ±10.8), but E did not inhibit the Col accumulation. Nx decreased the heart (Nx 1,002±28 vs. S 1,130±41 mg, p<0.05), but not liver weights and did not influence Col concentrations or protein/DNA ratios either in heart or liver. E potentiated the weight decrease of heart (NxE 862±20 vs. Nx 1,002±28 mg, p<0.01) and liver (NxE 8.3±0.44 vs. Nx 10.3±0.51 g, p<0.001) and Col accumulation (heart: NxE 113±6 vs. Nx 92±5 mg/100 g, p<0.01; liver: NxE 134±8 vs. Nx 101±9 mg/100 g, p<0.01). Nx did not influence either the soleus muscle weight or its Col accumulation, but it increased its protein/DNA ratio (Nx 66.3±4.7 vs. S 35.5±2.8 mg/100 g, p<0.01). E increased the Col concentration in muscle (NxE 141±3 vs. Nx 110±5 mg/100 g, p<0.01), while it attenuated the increase in protein/DNA ratio (NxE 36.6±2.1 vs. Nx 66.3±4.7, p<0.01). In conclusion, kidney ablation nephropathy stimulating kidney proliferation evokes only minor changes in heart, liver and striated muscle. E inhibits markedly the kidney proliferation and functional recovery, but does not prevent the Col accumulation. E evokes antiproliferative changes also in the heart and surprisingly even in the liver. Alterations in soleus muscle are only borderline.

          Related collections

          Author and article information

          Journal
          KBR
          Kidney Blood Press Res
          10.1159/issn.1420-4096
          Kidney and Blood Pressure Research
          S. Karger AG
          1420-4096
          1423-0143
          2000
          2000
          24 March 2000
          : 23
          : 2
          : 106-112
          Affiliations
          Institute of Preventive and Clinical Medicine, Bratislava, Slovak Republic
          Article
          25961 Kidney Blood Press Res 2000;23:106–112
          10.1159/000025961
          10765112
          © 2000 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 1, Tables: 5, References: 26, Pages: 7
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/25961
          Categories
          Original Paper

          Comments

          Comment on this article